Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
43.94
+1.89 (+4.49%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
Next >
These stocks are moving in today's after hours session
↗
November 03, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Insights into Xenon Pharmaceuticals's Upcoming Earnings
↗
October 31, 2025
Via
Benzinga
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast
↗
August 08, 2025
Via
Benzinga
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
↗
July 07, 2025
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
Via
Stocktwits
Earnings Scheduled For May 12, 2025
↗
May 12, 2025
Via
Benzinga
What to Expect from Xenon Pharmaceuticals's Earnings
↗
May 09, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Earnings Scheduled For November 12, 2024
↗
November 12, 2024
Via
Benzinga
Earnings Preview: Xenon Pharmaceuticals
↗
November 11, 2024
Via
Benzinga
Earnings Scheduled For August 11, 2025
↗
August 11, 2025
Via
Benzinga
Crude Oil Gains 3%; US Inflation Eases In April
↗
May 13, 2025
Via
Benzinga
Topics
Economy
This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
↗
May 07, 2025
Via
Benzinga
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
May 07, 2025
Via
Benzinga
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
↗
August 08, 2024
XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Outlook For Xenon Pharmaceuticals
↗
February 28, 2024
Via
Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
↗
December 08, 2023
Via
Benzinga
Xenon Pharmaceuticals: Q3 Earnings Insights
↗
November 08, 2023
Via
Benzinga
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
↗
May 09, 2024
XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
↗
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
↗
February 16, 2024
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...
Via
Benzinga
Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today
↗
November 30, 2023
Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542...
Via
Benzinga
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
November 28, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst
↗
November 27, 2023
Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20...
Via
Benzinga
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
November 27, 2023
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
↗
November 27, 2023
The company's epilepsy drug also showed promise as a depression treatment.
Via
Investor's Business Daily
What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today?
↗
November 27, 2023
Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of...
Via
Benzinga
Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday
↗
November 27, 2023
U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQ: ITRN) gained during Monday’s session after the company...
Via
Benzinga
Topics
Stocks
Why Is Neurocrine Biosciences Stock Trading Lower Today?
↗
November 10, 2023
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.